Buy SPL028 (SPL-028)
Buy SPL028 (SPL-028)
SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D2-DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders.[2][3][4][5] It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated.[2][6] SPL028’s route of administration is intravenous injection or intramuscular injection.[1]
Pharmacology
SPL028 shows similar pharmacodynamics as DMT in vitro.[2][6] Relatedly, SPL028 generalized with DMT in rodent drug discrimination tests.[6][7] On the other hand, SPL028 differs from DMT in terms of pharmacokinetics; it is more resistant to metabolism and shows a prolonged duration.[2][6][7] In a phase 1 clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans.[8]
Research
SPL028 was originated by Small Pharma and is under development by Cybin.[4] Small Pharma was acquired by Cybin in 2023.[9] As of February 2024, SPL028 is in phase 1 clinical trials.[4]
See also
- Substituted tryptamine
- List of investigational hallucinogens and entactogens
- CYB004 (deuterated dimethyltryptamine; dDMT)
- Deuterated 5-MeO-DMT
Reviews
There are no reviews yet.